From Serendipity to Intention: Development of Brain-Penetrant PARP1-Selective Inhibitors-Reference-Cited by-同舟云学术

From Serendipity to Intention: Development of Brain-Penetrant PARP1-Selective Inhibitors

Published:2024-01-22 Issue:7 Volume:30 Page:1217-1219
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:

Author:

Lynce Filipa¹²³^ORCID,Lin Nancy U.¹²^ORCID

Affiliation:

1. 1Division of Breast Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

2. 2Harvard Medical School, Boston, Massachusetts.

3. 3Center for BRCA and Related Genes, Dana-Farber Cancer Institute, Boston, Massachusetts.

Abstract

Summary Primary and secondary brain tumors cause significant mortality and constitute an important unmet need. The development of AZD9574, a brain-penetrant, PARP1-selective inhibitor with favorable pharmacologic properties and intriguing preclinical activity, has led to an ongoing clinical trial evaluating it alone and in combination with temozolomide or antibody drug conjugates. See related article by Staniszewska et al., p. 1338

Publisher

American Association for Cancer Research (AACR)

Link

https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-23-3571/3405695/ccr-23-3571.pdf

Reference22 articles.

1. Preclinical characterization of AZD9574, a blood-brain barrier penetrant inhibitor of PARP1;Staniszewska;Clin Cancer Res,2024

2. Epidemiology of brain metastases and leptomeningeal disease;Lamba;Neuro Oncol,2021

3. Brain and other central nervous system tumor statistics, 2021;Miller;CA Cancer J Clin,2021

4. Patterns of recurrence and metastasis in BRCA1/2 associated breast cancer;Song;Cancer,2020

5. Clinicopathologic and genomic landscape of breast carcinoma brain metastases;Huang;Oncologist,2021